Aortic Aneurysm Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Aortic aneurysm treatment encompasses the full spectrum of management strategies for pathological dilatation of the aorta — from conservative surveillance and cardiovascular risk reduction in small aneurysms, through elective repair of aneurysms reaching size thresholds, to emergency intervention for ruptured or symptomatic aneurysms. An aortic aneurysm is diagnosed when the aortic diameter exceeds 1.5 times the expected normal size; the main clinical concern is rupture, which is associated with catastrophic haemorrhage and mortality exceeding 80% overall.

The treatment decision is fundamentally a risk-benefit analysis: the rupture risk of an untreated aneurysm (which increases steeply with diameter — from 0.5% per year at 4 cm to over 25% per year at 7 cm) is weighed against the procedural risk of elective repair (1–5% depending on technique and patient fitness). For aneurysms below the intervention threshold, medical treatment to reduce cardiovascular risk and slow aneurysm growth is the primary therapeutic activity, with imaging surveillance to track dimensions.

The three pillars of aortic aneurysm management are: surveillance (regular ultrasound or CT imaging to monitor size), risk factor modification (smoking cessation, blood pressure control, statin therapy), and elective repair when size or symptoms dictate. The critical public health challenge is early detection — many AAAs are entirely asymptomatic until they rupture, making screening programmes essential. The UK NHS AAA Screening Programme, which invites all 65-year-old men for a single abdominal ultrasound, has been shown to reduce AAA-related mortality by approximately 50%.

Infrarenal abdominal aortic aneurysm (AAA) is by far the most common aortic aneurysm, with prevalence of 4–8% in men over 65. Screening and monitoring protocols classify AAAs by size: small (3.0–4.4 cm — annual ultrasound surveillance), medium (4.5–5.4 cm — 3-monthly surveillance), and large (greater than 5.5 cm — referral for repair assessment). Aneurysms in women warrant more aggressive intervention thresholds due to higher sex-specific rupture risk at smaller diameters.

Thoracic aortic aneurysms (TAA) involve the ascending aorta (treated by open sternotomy), aortic arch (requiring complex open surgery with circulatory arrest), or descending thoracic aorta (amenable to TEVAR in most cases). Thoracoabdominal aneurysms (TAAA) span both compartments and require the most complex repair, with significant risk of paraplegia from spinal artery compromise. Inflammatory aneurysms — a rare variant involving periaortic fibrosis — may respond to corticosteroid therapy in early phases. Mycotic (infected) aneurysms from bacteraemia require antibiotic therapy combined with surgical debridement and in-situ or extra-anatomic bypass grafting.

Medical management with surveillance, statin therapy, blood pressure control, and smoking cessation is appropriate for all patients with known aortic aneurysm regardless of size, as cardiovascular risk reduction benefits extend beyond aneurysm-specific outcomes. Elective repair is recommended for aneurysms meeting size criteria (AAA greater than 5.5 cm men / 5.0 cm women), rapidly growing aneurysms (greater than 1 cm/year), symptomatic aneurysms, and aneurysms with associated complications (mural thrombus embolisation, contained rupture).

Patient fitness for repair is assessed comprehensively: cardiopulmonary exercise testing (CPET) — specifically peak VO2 (oxygen consumption at maximum exercise) — is used to risk-stratify patients. Peak VO2 below 10 mL/kg/min identifies very high-risk patients for whom the procedural risk may equal or exceed the rupture risk, and for whom EVAR (if anatomically suitable) or conservative management may be preferable. All patients should receive detailed risk-benefit counselling before committing to elective repair, with absolute and relative numerical risks explained clearly.

Conservative management combines regular imaging surveillance (ultrasound for most AAAs, CT angiography when repair planning is needed), statin therapy (to LDL below 1.8 mmol/L — associated with 1–2 mm/year reduced growth rate in meta-analyses), antihypertensive therapy (beta-blockers and ACE inhibitors most evidence — targeting systolic BP below 130 mmHg), and smoking cessation (the single most important modifiable risk factor for both aneurysm progression and rupture risk).

When repair is indicated, the two techniques — EVAR (endovascular aneurysm repair using a catheter-delivered stent-graft) and open surgical repair using a Dacron graft — are the definitive options. EVAR is preferred for older, frailer patients given its lower 30-day mortality, while open repair is preferred for younger, fitter patients given its superior long-term durability and freedom from endoleak surveillance. For thoracic aneurysms, TEVAR (thoracic EVAR) is suitable for the descending aorta; ascending and arch aneurysms require open cardiac surgery with cardiopulmonary bypass and hypothermic circulatory arrest. Fenestrated and branched EVAR (FEVAR, BEVAR) extend endovascular repair to complex juxta- and para-renal aneurysms by incorporating side branches into the stent-graft to maintain visceral artery perfusion.

Selecting the most appropriate Aortic Aneurysm Treatment approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

Elective aortic aneurysm repair eliminates the rupture risk — a life-saving benefit most starkly illustrated by the 80–85% mortality of untreated rupture versus the 1–3% operative mortality of elective EVAR. Successful EVAR or open repair returns the patient's aorta to a functioning, non-aneurysmal conduit. In fit patients undergoing elective repair, life expectancy is comparable to age-matched peers without aneurysm.

The NHS AAA Screening Programme has demonstrated 53% reduction in AAA-related mortality in the invited population after 13 years of follow-up. Medical risk factor management with statins, antihypertensives, and smoking cessation reduces cardiovascular mortality — which is the leading cause of death in AAA patients — significantly beyond the aneurysm-specific benefit. Well-executed post-EVAR surveillance programmes detect endoleaks and device complications before they result in clinical aneurysm-related events in the vast majority of cases.

The risks of untreated large aortic aneurysm — rupture — substantially exceed the risks of elective repair in fit patients. Rupture of a 7 cm AAA carries approximately 80% overall mortality (including pre-hospital deaths). However, elective repair carries its own risks: EVAR procedural mortality of 0.5–1.7% and open repair mortality of 2–5% in specialist centres, rising substantially in higher-risk patients and lower-volume centres.

Long-term treatment-specific risks include EVAR complications (endoleak in 10–20%, device migration, limb occlusion, secondary intervention in approximately 15–20% of patients at 5 years) requiring lifelong CT surveillance. Open repair complications include graft infection (0.5–1% — a serious life-threatening complication requiring re-operation and antibiotic therapy), graft-enteric fistula, and aorto-enteric fistula presenting with GI bleeding. The IMPROVE trial for ruptured AAA demonstrated equivalent outcomes between EVAR and open repair, with EVAR associated with faster recovery and shorter hospital stay in survivors.

Patients on conservative surveillance attend vascular outpatient clinics every 3–12 months depending on aneurysm size, with abdominal ultrasound at each visit. An aneurysm approaching intervention threshold (4.5–5.4 cm) should be reviewed by a vascular surgeon to discuss repair options and patient fitness assessment. All patients on surveillance should have statin therapy, blood pressure optimisation, antiplatelet therapy (aspirin), and smoking cessation support actively maintained.

After EVAR, CT angiography at 1 month and 12 months is standard, with annual duplex ultrasound surveillance thereafter in stable patients. All patients with Type I or III endoleak require re-intervention. After open repair, surveillance is less intensive but annual clinical review with blood pressure check and examination of the graft region is recommended. Patients who have undergone open repair should receive life-long penicillin V prophylaxis before dental procedures to prevent graft seeding from bacteraemia.

Medical management for small AAA is very low cost: statin therapy, antihypertensives, and annual ultrasound together cost approximately $500–1,500 per year in the US. Surveillance ultrasound is straightforward and widely available. Elective EVAR in the United States costs $50,000–100,000 including the stent-graft device ($10,000–30,000 for the device itself). Open repair costs $30,000–70,000. Life-long EVAR surveillance adds annual costs of $500–1,500 per year.

For patients seeking treatment abroad, India offers comprehensive aortic aneurysm management at JCI-accredited vascular centres at a fraction of Western costs: EVAR for $8,000–18,000 and open repair for $6,000–14,000. Surveillance imaging in India costs $50–200 per ultrasound and $200–400 per CT angiography. Leading vascular surgery programmes at Apollo, Fortis, and Manipal hospitals have performed thousands of AAA repairs and use imported stent-graft systems identical to those used in Western centres. Turkey, Thailand, and Malaysia offer comparable quality at similar price points.

For aneurysms below the intervention threshold, ongoing surveillance with risk factor optimisation remains the standard of care. No pharmacological agent has been proven in randomised controlled trials to prevent rupture of large aneurysms already meeting size criteria — the evidence for repair in this group is overwhelming. For the subset of patients too frail for any surgical intervention, best supportive care with opioid analgesia for comfort in the event of rupture is the appropriate pathway, with advance care planning discussions.

Emerging approaches include endovascular sealing (using polymers or biologically active materials injected into the aneurysm sac to promote thrombosis and wall stabilisation), which is in early clinical investigation. Doxycycline (a matrix metalloproteinase inhibitor) has shown promise in small clinical studies for slowing AAA growth, though a definitive large RCT remains awaited. Laparoscopic-assisted open repair of AAA is a hybrid approach reducing the morbidity of open surgery in selected patients at experienced centres.